Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coherus Inks $300m Credit Agreement With Ranibizumab Approval Worth $50m

US Biotech Also Reveals Latest Progress With On-Body Pegfilgrastim Injector

Executive Summary

Presenting at the 40th Annual J.P. Morgan Health Care Conference, Coherus BioSciences provided the latest on the firm’s highly-anticipated proposed on-body injector device for pegfilgrastim, days after securing a $300m credit agreement that includes $50m related to the firm’s proposed ranibizumab biosimilar.

You may also be interested in...



What’s Next? Five Things To Look Out For In August

A busy August brings patent expiries, biosimilar target action dates and the potential for a major change to biosimilar prescribing guidelines in Germany.

Coherus’ Pegfilgrastim Sales Fall $150m In 2021 As Firm Plans On-Body

Coherus BioSciences has posted a massive loss for 2021 due to tumbling revenues, as well as continued investment in its pipeline projects, not least the proposed on-body injector device for its pegfilgrastim biosimilar alongside a ranibizumab asset.

Finance Watch: SPACs Lose Their Luster As Difficulties Mount

Public Company Edition: While panelists at Biotech Showcase argued merging with a special purpose acquisition corporation is not as attractive as it used to be, firms continue to pursue this go-public alternative. Also, Hillstream launched a small IPO and Cytokinetics accessed cash from Royalty Pharma. 

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB151544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel